December 12, 2017 08:14 AM EST
R&D

#ASH17: Ab­b­Vie, Roche boast stel­lar PhI­II leukemia da­ta for a “break­through” com­bo with block­buster am­bi­tions

John Carroll

Editor & Founder

Ab­b­Vie and Roche rolled out the full bat­tery of im­pres­sivePhase III da­ta for their com­bi­na­tion of Ven­clex­ta and Rit­ux­an, mak­ing a case at ASH that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times